Google Académico | Citações: 16429 | índice h: 32 | índice i10: 482
Complejo Acinetobacter baumannii-calcoaceticus: virulencia y resistencia antimicrobiana
PDF (portugués (Brasil))

Palabras clave

Acinetobacter
Resistencia bacteriana
Virulencia bacteriana

Cómo citar

Complejo Acinetobacter baumannii-calcoaceticus: virulencia y resistencia antimicrobiana. (2026). Revista Eletrônica Acervo Saúde, 26(8), e24644. https://doi.org/10.25248/reas.e24644.2026

Copyright © | Todos los derechos reservados.

La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.

Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.

Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.

Resumen

Objetivo: Reunir información relacionada con el complejo Acinetobacter baumannii - calcoaceticus, incluyendo sus características, virulencia y resistencia antimicrobiana. Caracterizar los genes asociados con estos factores y abordar el aumento de la resistencia bacteriana a los antimicrobianos. Revisión bibliográfica: Acinetobacter es uno de los patógenos más frecuentes en las Infecciones Asociadas a la Atención de la Salud (IAAS), con una alta prevalencia de aislados multirresistentes (MDR). A. baumannii fue una de las especies bacterianas con mayor incidencia durante la pandemia de la COVID-19. Los factores de virulencia permiten la supervivencia bacteriana en ambientes abióticos, favoreciendo su persistencia en entornos hospitalarios. Aislados resistentes productores de betalactamasas han sido reportados en todo el mundo. Los aminoglucósidos se convirtieron en una alternativa terapéutica; sin embargo, la resistencia a estos fármacos los volvió ineficaces en el 50–87% de los aislados. Las tetraciclinas mostraron eficacia variable, con tasas de resistencia inferiores al 20% en Europa y superiores al 70% en países africanos. Las polimixinas B y E fueron reintroducidas en la práctica clínica; no obstante, el uso continuo de estos fármacos ha incrementado el número de aislados resistentes. En consecuencia, la terapia combinada con antimicrobianos ha sido ampliamente estudiada, aunque las divergencias entre los estudios dificultan la estandarización de protocolos terapéuticos. Consideraciones finales: La elevada capacidad de Acinetobacter para persistir en ambientes hospitalarios, junto con la alta incidencia de aislados MDR y la dificultad para establecer protocolos terapéuticos efectivos, resalta la necesidad crítica de desarrollar nuevas estrategias terapéuticas.

PDF (portugués (Brasil))

Referencias

ANVISA, Agência Nacional de Vigilância Sanitária. Plano nacional para a prevenção e o controle de resistência microbiana nos serviços de saúde. 2017.

ANVISA, Agência Nacional de Vigilância Sanitária. NOTA TÉCNICA GVIMS/GGTES/ANVISA No 02/2015 Orientações gerais para a implantação da Sub-rede Analítica de Resistência Microbiana em Serviços de Saúde. 2015.

BHANDARI S, et al. Biofilm formation capacity and Carbapenem-resistance in Acinetobacter-calcoaceticus-baumannii isolated from inpatients in a tertiary care hospital in Nepal. BMC Research Notes, 2025; 18(1): 225.

BORCAN AM, et al. Trends in Antimicrobial Resistance of Acinetobacter baumannii and Pseudomonas aeruginosa from Bloodstream Infections: An Eight-Year Study in a Romanian Tertiary Hospital. Pharmaceuticals, 2025; 18(7): 948.

BOSTANGHADIRI N, et al. Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. Antimicrobial Resistance & Infection Control, 2024; 13(1): 24.

CASTANHEIRA M, et al. Global epidemiology and mechanisms of resistance of Acinetobacter baumannii-calcoaceticus complex. Clinical Infectious Diseases, 2023; 76(Supplement_2): S166-S178.

CHOUDHARY J, SHARIFF M. Characterization of carbapenem-resistant biofilm forming Acinetobacter baumannii isolates from clinical and surveillance samples. Scientific Reports, 2025; 15(1): 33892.

CONCEIÇÃO-NETO C, et al. Detection of the plasmid-mediated mcr-1 gene in clinical KPC-2-producing Escherichia coli isolates in Brazil. International Journal of Antimicrobial Agents, 2017; 50(2): 282.

COSGAYA C, et al. In vitro and in vivo Virulence Potential of the Emergent Species of the Acinetobacter baumannii (Ab) Group. Frontiers in microbiology, 2019; 10: 2429.

DURANTE-MANGONI E, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clinical Infectious Diseases, 2013; 57(3): 349-358.

EL HAFA H, et al. Dissemination of carbapenem-resistant Acinetobacter baumannii strains carrying the blaGES, blaNDM and blaOXA23 in Morocco. Germs, 2019; 9(3): 133.

FALAGAS ME, et al. Global epidemiology and antimicrobial resistance of Metallo-β-Lactamase (MBL)-producing Acinetobacter clinical isolates: a systematic review. Pathogens, 2025; 14(6): 557.

GALLARDO-GODOY A, et al. Structure-Function Studies of Polymyxin B Lipononapeptides. Molecules, 2019; 24(3): 553.

GROSSMAN TH. Tetracycline antibiotics and resistance. Cold Spring Harbor Perspectives in Medicine, 2016; 6(4): a025387.

GUO Y, et al. Antimicrobial resistance profile of clinical isolates from hospitals across China: CHINET 2024 surveillance report. One Health Advances, 2025; 3(1): 23.

HARDING CM, et al. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nature Reviews Microbiology, 2018; 16(2): 91-102.

HARMER CJ, et al. Acinetobacter baumannii GC2 Sublineage Carrying the aac(6')-Im Amikacin, Netilmicin, and Tobramycin Resistance Gene Cassette. Antimicrobial Agents and Chemotherapy, 2023; 67(8): e00486-23.

IYER R, et al. Acinetobacter baumannii OmpA is a selective antibiotic permeant porin. ACS Infectious Diseases, 2017; 4(3): 373-381.

JIE J, et al. Prognostic Indicators of Carbapenem‐Resistant Acinetobacter baumannii Infection: A Meta‐Analysis and Systematic Review. Health Science Reports, 2025; 8(12): e71639.

KAVIAR VH, et al. Antibiotic resistance pattern and biofilm formation among clinical Acinetobacter baumannii isolates: A cross-sectional study. Journal of Acute Disease, 2025; 1(41): 5.

KINOSHITA Y, et al. Study of the structure-activity relationship of polymyxin analogues. Bioorganic & Medicinal Chemistry Letters, 2018; 28(16): 2713-2716.

LAPLANTE KL, et al. Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance. Annals of Medicine, 2022; 54(1): 1686-1700.

MANDAL SM, PAUL D. Bacterial Adaptation to Co-resistance. Springer: Cham, 2020.

MARINOVA-BULGARANOVA T, et al. Current Methods for Reliable Identification of Species in the Acinetobacter calcoaceticus–Acinetobacter baumannii Complex. Microorganisms, 2025; 13(8): 1819.

MEA HJ, et al. An overview of Acinetobacter baumannii pathogenesis: Motility, adherence and biofilm formation. Microbiological research, 2021; 247: 126722.

NADERI G, et al. Mobile genetic elements carrying aminoglycoside resistance genes in Acinetobacter baumannii isolates belonging to global clone 2. Frontiers in Microbiology, 2023; 14: 1172861.

ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization: Genebra, 2019.

ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. World Health Organization: Genebra, 2025.

PAUL M, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. The Lancet Infectious Diseases, 2018; 18(4): 391-400.

PIPERAKI ET, et al. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clinical Microbiology and Infection, 2019; 25(8): 951-957.

PROCOP GW, et al. Koneman Diagnóstico Microbiológico: texto e atlas. 7. ed. Guanabara Koogan: Rio de Janeiro-RJ, 2018.

QIN Q, et al. Colistin Resistance Mechanism and Management Strategies of Colistin-Resistant Acinetobacter baumannii Infections. Pathogens, 2024; 13(12): 1049.

RAJKUMARI S, et al. Prevalence and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital. Journal of College of Medical Sciences-Nepal, 2020; 16(1): 26-32.

SEOK H, et al. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB): A multicentre study in Korea. Journal of Global Antimicrobial Resistance, 2021; 24: 429-439.

TAMMA PD, et al. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clinical Infectious Diseases, 2024; 78(5): e1-e40.

VILLALÓN P et al. Dynamics of a sporadic nosocomial Acinetobacter calcoaceticus–Acinetobacter baumannii complex population. Frontiers in microbiology, 2019; 10: 593.

YEHYA A, et al. The intricacies of Acinetobacter baumannii: a multifaceted comprehensive review of a multidrug-resistant pathogen and its clinical significance and implications. Frontiers in microbiology, 2025; 16: 1565965.

ZARRILLI R et al. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Italy. Ann Ig, 2021; 33(5): 401-9.